altimmune glp 1 Pemvidutide Altimmune: GLP-1/Glucagon Receptor Agonist Pemvidutide

Individual GLP-1 telehealth programs are reviewed with attention to how providers typically operate in practice

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks

Glucagon-like peptide-1 (GLP-1) receptor agonists, introduced in 2005, have become crucial in managing type 2 diabetes mellitus (T2DM) by regulating g..

Increases GLP-1 naturally *based on preclinical studies

Conclusion A population pharmacokinetic model incorporating allometric scaling was developed to simultaneously describe the PK of semaglutide in all animal species and predict its PK in humans

Across the research so far: ~54% fewer alcohol-related events ~45% lower relapse 3050% lower odds of developing AUD